- Home
- ADTX vs GLTO Comparison
ADTX vs GLTO Comparison
Compare ADTX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- GLTO
- Stock Information
- Founded
- ADTX 2017
- GLTO 2011
- Country
- ADTX United States
- GLTO Denmark
- Employees
- ADTX N/A
- GLTO N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ADTX Health Care
- GLTO Health Care
- Exchange
- ADTX Nasdaq
- GLTO Nasdaq
- Market Cap
- ADTX 4.9M
- GLTO 4.5M
- IPO Year
- ADTX 2020
- GLTO 2020
- Fundamental
- Price
- ADTX $0.67
- GLTO $18.03
- Analyst Decision
- ADTX
- GLTO Buy
- Analyst Count
- ADTX 0
- GLTO 1
- Target Price
- ADTX N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ADTX 342.1K
- GLTO 6.9M
- Earning Date
- ADTX 11-17-2025
- GLTO 10-31-2025
- Dividend Yield
- ADTX N/A
- GLTO N/A
- EPS Growth
- ADTX N/A
- GLTO N/A
- EPS
- ADTX N/A
- GLTO N/A
- Revenue
- ADTX $12,051.00
- GLTO N/A
- Revenue This Year
- ADTX $15,768.94
- GLTO N/A
- Revenue Next Year
- ADTX N/A
- GLTO N/A
- P/E Ratio
- ADTX N/A
- GLTO N/A
- Revenue Growth
- ADTX N/A
- GLTO N/A
- 52 Week Low
- ADTX $0.67
- GLTO $2.01
- 52 Week High
- ADTX $464.98
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- ADTX 26.68
- GLTO 93.65
- Support Level
- ADTX $0.97
- GLTO $3.64
- Resistance Level
- ADTX $0.77
- GLTO $4.13
- Average True Range (ATR)
- ADTX 0.07
- GLTO 1.51
- MACD
- ADTX -0.02
- GLTO 1.07
- Stochastic Oscillator
- ADTX 1.51
- GLTO 60.67
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.